Advertisement

Naunyn-Schmiedeberg's Archives of Pharmacology

, Volume 388, Issue 11, pp 1201–1209 | Cite as

Effects of Tanshinone IIA on osteogenic differentiation of mouse bone marrow mesenchymal stem cells

  • Kejun Qian
  • Huazhong Xu
  • Teng Dai
  • Keqing ShiEmail author
Original Article

Abstract

Tanshinone IIA (TSA) is a lipophilic diterpene purified from the Chinese herb Danshen, which exhibits potent antioxidant and anti-inflammatory properties. Effect of TSA remains largely uninvestigated on the osteogenic differentiation of bone marrow mesenchymal stem cells (BM-MSCs), which are widely used in cell-based therapy of bone diseases. In the present study, both ALP activity at day 7 and calcium content at day 24 were upregulated during the osteogenesis of mouse BM-MSCs treated with TSA (1 and 5 μM), demonstrating that it promoted the osteogenesis at both early and late stages. We found that TSA promoted osteogenesis and inhibited osteoclastogenesis, evident by RT-PCR analysis of osteogenic marker gene expressions. However, osteogenesis was inhibited by TSA at 20 μM. We further revealed that TSA (1 and 5 μM) upregulated BMP and Wnt signaling. Co-treatment with Wnt inhibitor DKK-1 or BMP inhibitor noggin significantly decreased the TSA-promoted osteogenesis, indicating that upregulation of BMP and Wnt signaling plays a significant role and contributes to the TSA-promoted osteogenesis. Of clinical interest, our study suggests TSA as a promising therapeutic strategy during implantation of BM-MSCs for a more effective treatment of bone diseases.

Keywords

Tanshinone IIA Bone disease Mesenchymal stem cells Osteogenesis Osteoclastogenesis 

Notes

Acknowledgments

None.

Funding

None.

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.

Supplementary material

210_2015_1154_MOESM1_ESM.docx (166 kb)
ESM 1 ESM 1 file contains analysis of cell viability, ROS production under TSA treatment. (DOCX 166 kb)

References

  1. Beyer Nardi N, da Silva ML (2006) Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 249–282Google Scholar
  2. Boyce BF, Xing L (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473:139–146PubMedCentralCrossRefPubMedGoogle Scholar
  3. Brighton CT, Hunt RM (1997) Early histologic and ultrastructural changes in microvessels of periosteal callus. J Orthop Trauma 11:244–253CrossRefPubMedGoogle Scholar
  4. Chen Z, Xu H (2014) Anti-inflammatory and immunomodulatory mechanism of tanshinone IIA for atherosclerosis. Evid-Based Complement Alternat Med 2014:267976PubMedCentralPubMedGoogle Scholar
  5. Dai ZK, Qin JK, Huang JE, Luo Y, Xu Q, Zhao HL (2012) Tanshinone IIA activates calcium-dependent apoptosis signaling pathway in human hepatoma cells. J Nat Med 66:192–201CrossRefPubMedGoogle Scholar
  6. Digirolamo CM, Stokes D, Colter D, Phinney DG, Class R, Prockop DJ (1999) Propagation and senescence of human marrow stromal cells in culture: a simple colony-forming assay identifies samples with the greatest potential to propagate and differentiate. Br J Haematol 107:275–281CrossRefPubMedGoogle Scholar
  7. Dong X, Dong J, Zhang R, Fan L, Liu L, Wu G (2009) Anti-inflammatory effects of tanshinone IIA on radiation-induced microglia BV-2 cells inflammatory response. Cancer Biother Radiopharm 24:681–687CrossRefPubMedGoogle Scholar
  8. Fan GW, Gao XM, Wang H, Zhu Y, Zhang J, Hu LM, Su YF, Kang LY, Zhang BL (2009) The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol 113:275–280CrossRefPubMedGoogle Scholar
  9. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P (2007) Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol 568:213–221CrossRefPubMedGoogle Scholar
  10. Horwitz EM, Prockop DJ, Fitzpatrick LA, Koo WW, Gordon PL, Neel M, Sussman M, Orchard P, Marx JC, Pyeritz RE, Brenner MK (1999) Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 5:309–313CrossRefPubMedGoogle Scholar
  11. Kim HJ, Kim SH (2010) Tanshinone IIA enhances BMP-2-stimulated commitment of C2C12 cells into osteoblasts via p38 activation. Amino Acids 39:1217–1226CrossRefPubMedGoogle Scholar
  12. Kobayashi Y (2012) Roles of Wnt signaling in bone metabolism. Clin Calcium 22:1701–1706PubMedGoogle Scholar
  13. Kwak HB, Yang D, Ha H, Lee JH, Kim HN, Woo ER, Lee S, Kim HH, Lee ZH (2006) Tanshinone IIA inhibits osteoclast differentiation through down-regulation of c-Fos and NFATc1. Exp Mol Med 38:256–264CrossRefPubMedGoogle Scholar
  14. Kwak HB, Sun HM, Ha H, Kim HN, Lee JH, Kim HH, Shin HI, Lee ZH (2008) Tanshinone IIA suppresses inflammatory bone loss by inhibiting the synthesis of prostaglandin E2 in osteoblasts. Eur J Pharmacol 601:30–37CrossRefPubMedGoogle Scholar
  15. Lam BY, Lo AC, Sun X, Luo HW, Chung SK, Sucher NJ (2003) Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice. Phytomedicine 10:286–291CrossRefPubMedGoogle Scholar
  16. Lin C, Wang L, Wang H, Yang L, Guo H, Wang X (2013) Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways. J Cell Biochem 114:2061–2070CrossRefPubMedGoogle Scholar
  17. Liu YW, Huang YT (2014) Inhibitory effect of tanshinone IIA on rat hepatic stellate cells. PLoS One 9:e103229PubMedCentralCrossRefPubMedGoogle Scholar
  18. Liu X, Guo CY, Ma XJ, Wu CF, Zhang Y, Sun MY, Pan YT, Yin HJ (2015) Anti-inflammatory effects of tanshinone IIA on atherosclerostic vessels of ovariectomized ApoE mice are mediated by estrogen receptor activation and through the ERK signaling pathway. Cell Physiol Biochem 35:1744–1755CrossRefPubMedGoogle Scholar
  19. Marcellini S, Henriquez JP, Bertin A (2012) Control of osteogenesis by the canonical Wnt and BMP pathways in vivo: cooperation and antagonism between the canonical Wnt and BMP pathways as cells differentiate from osteochondroprogenitors to osteoblasts and osteocytes. Bioessays 34:953–962CrossRefPubMedGoogle Scholar
  20. Oni OO (1992) Early histological and ultrastructural changes in medullary fracture callus. J Bone Joint Surg Am 74:633–634PubMedGoogle Scholar
  21. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 284:143–147CrossRefPubMedGoogle Scholar
  22. Redlich K, Smolen JS (2012) Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov 11:234–250CrossRefPubMedGoogle Scholar
  23. Ren ZH, Tong YH, Xu W, Ma J, Chen Y (2010) Tanshinone II A attenuates inflammatory responses of rats with myocardial infarction by reducing MCP-1 expression. Phytomedicine 17:212–218CrossRefPubMedGoogle Scholar
  24. Shang Q, Wang H, Li S, Xu H (2013) The effect of sodium tanshinone IIA sulfate and simvastatin on elevated serum levels of inflammatory markers in patients with coronary heart disease: a study protocol for a randomized controlled trial. Evid Based Complement Alternat Med 2013:756519PubMedCentralPubMedGoogle Scholar
  25. Wauquier F, Leotoing L, Coxam V, Guicheux J, Wittrant Y (2009) Oxidative stress in bone remodelling and disease. Trends Mol Med 15:468–477CrossRefPubMedGoogle Scholar
  26. Wilson CG, Martin-Saavedra FM, Vilaboa N, Franceschi RT (2013) Advanced BMP gene therapies for temporal and spatial control of bone regeneration. J Dent Res 92:409–417PubMedCentralCrossRefPubMedGoogle Scholar
  27. Xu S, Liu P (2013) Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat 23:149–153CrossRefPubMedGoogle Scholar
  28. Yang R, Liu A, Ma X, Li L, Su D, Liu J (2008) Sodium tanshinone IIA sulfonate protects cardiomyocytes against oxidative stress-mediated apoptosis through inhibiting JNK activation. J Cardiovasc Pharmacol 51:396–401CrossRefPubMedGoogle Scholar
  29. Yang L, Guo H, Dong L, Wang L, Liu C, Wang X (2014) Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells. Oncol Rep 32:1303–1311PubMedGoogle Scholar
  30. Yin X, Yin Y, Cao FL, Chen YF, Peng Y, Hou WG, Sun SK, Luo ZJ (2012) Tanshinone IIA attenuates the inflammatory response and apoptosis after traumatic injury of the spinal cord in adult rats. PLoS One 7:e38381PubMedCentralCrossRefPubMedGoogle Scholar
  31. Yu Q, Chen H, Sheng L, Liang Y, Li Q (2014) Sodium tanshinone IIA sulfonate prolongs the survival of skin allografts by inhibiting inflammatory cell infiltration and T cell proliferation. Int Immunopharmacol 22:277–284CrossRefPubMedGoogle Scholar
  32. Zhang L, Gan W, An G (2012) Influence of Tanshinone IIa on heat shock protein 70, Bcl-2 and Bax expression in rats with spinal ischemia/reperfusion injury. Neural Regen Res 7:2882–2888PubMedCentralPubMedGoogle Scholar
  33. Zhou L, Zuo Z, Chow MS (2005) Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 45:1345–1359CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2015

Authors and Affiliations

  1. 1.Department of Orthopaedic SurgeryNanjing Medical University Affiliated Wuxi Second HospitalWuxiChina

Personalised recommendations